Apparently, the street don't think it would be a good idea for the corp to take on relistor sale by itself. WYE's sale force was not good, effective to do the job; then what make this management think they would be better?

Before a good relistor partner is signed up, we are not going to higher. To sign a good partner, it may require a clean one year safety trial.

If oral relistor phase II data is nearly effective as injectable, then, we do just fine after oral relistor data are published in near future.

Someone want to be out PGNX before the end of October which is deadline for the institution so that they could claim their investment loss,